Seegene, Inc.

Equities

A096530

KR7096530001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
21,900 ^KRW	0.00%		+2.10%	-4.37%

Mar. 14	Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 24	Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases	CI

Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.

March 28, 2023 at 03:36 am EDT

From October 1, 2022 to December 31, 2022, the company has repurchased 701,262 shares, representing 1.39% for KRW 20,887.29 million. With this, the company has completed the repurchase of 701,262 shares, representing 1.39% for KRW 20,887.29 million under the buyback announced on September 28, 2022.

Latest news about Seegene, Inc.

Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases	Jan. 24	CI
Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy; Expanded Collaboration Aims To Improve Syndromic Infectious Disease Testing	Dec. 14	MT
Microbix Brief: Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy	Dec. 14	MT
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on July 13, 2023.	23-10-13	CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023.	23-08-28	CI
Seegene, Inc.'s Equity Buyback announced on February 28, 2023, has expired with 2,046,354 shares, representing 4.11% for KRW 49,998.4 million.	23-08-27	CI
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC	23-07-31	CI
Seegene, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.	23-07-12	CI
Seegene, Inc. authorizes a Buyback Plan.	23-07-12	CI
Seegene, Inc. and Werfen Partner to Collaborate on Onesystem Business to Develop Syndromic qPCR Assays	23-06-14	CI
Seegene and Werfen Partner to Collaborate on OneSystem(TM) Business to Develop Syndromic qPCR Assays	23-06-14	CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023.	23-05-30	CI
Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.	23-03-28	CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.	23-03-28	CI
Seegene, Inc.'s Equity Buyback announced on September 28, 2022, has expired with 1,780,608 shares, representing 3.56% for KRW 49,330.84 million.	23-03-27	CI
Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	23-02-28	CI
Seegene, Inc. authorizes a Buyback Plan.	23-02-27	CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.	22-12-29	CI
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.	22-09-28	CI
Seegene, Inc. authorizes a Buyback Plan.	22-09-27	CI

Chart Seegene, Inc.

Duration

Period

More charts

Company Profile

Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Seegene, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
SEEGENE, INC.	-4.37%	733M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M
CURIOX BIOSYSTEMS CO., LTD	+13.32%	332M

Bio Diagnostics & Testing